NPI: 1639613649 · BRIDGETON, NJ 08302 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 12/09/2016
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 12/09/2016 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 16,801 | $995K |
| 2019 | 17,341 | $774K |
| 2020 | 14,727 | $937K |
| 2021 | 11,811 | $504K |
| 2022 | 9,771 | $230K |
| 2023 | 6,219 | $241K |
| 2024 | 4,292 | $232K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | 29,260 | 2,280 | $3.23M | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 15,310 | 1,158 | $293K |
| J1270 | Injection, doxercalciferol, 1 mcg | 16,432 | 1,400 | $210K |
| J1756 | Injection, iron sucrose, 1 mg | 5,565 | 1,196 | $54K |
| A4657 | Syringe, with or without needle, each | 8,515 | 1,995 | $29K |
| 83970 | 700 | 619 | $15K | |
| 85048 | 1,029 | 876 | $15K | |
| 85041 | 1,029 | 877 | $15K | |
| 83550 | 519 | 457 | $12K | |
| 83540 | 520 | 457 | $12K | |
| 82728 | 554 | 488 | $12K | |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 144 | 94 | $8K |
| 82108 | 126 | 121 | $3K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 118 | 90 | $3.22 |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 431 | 163 | $0.00 |
| OP250 | 710 | 25 | $0.00 |